|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Establishing proof of concept:Platelet-rich plasma and bone marrow aspirate concentrate may improve cartilage repair following surgical treatment for osteochondral lesions of the talus显示文摘Osteochondral lesions of the talus are common injuries in the athletic patient. They present a challenging clinical problem as cartilage has a poor potential for healing. Current surgical treatments consist of reparative(microfracture) or replacement(autologous osteochondral graft) strategies and demonstrate good clinical outcomes at the short and medium term follow-up. Radiological findings and second-look arthroscopy however, indicate possible poor cartilage repair with evidence of fibrous infill and fissuring of the regenerative tissue following microfracture. Longer-term follow-up echoes these findings as it demonstrates a decline in clinical outcome. The nature of the cartilage repair that occurs for an osteochondral graft to become integrated with the native surround tissue is also of concern. Studies have shown evidence of poor cartilage integration,with chondrocyte death at the periphery of the graft, possibly causing cyst formation due to synovial fluid ingress. Biological adjuncts, in the form of platelet-rich plasma(PRP) and bone marrow aspirate concentrate(BMAC), have been investigated with regard to their potential in improving cartilage repair in both in vitro and in vitro settings. The in vitro literature indicates that these biological adjuncts may increase chondrocyte proliferation as well as synthetic capability, while limiting the catabolic effects of an inflammatory joint environment. These findings have been extrapolated to in vitro animal models, with results showing that both PRP and BMAC improve cartilage repair. The basic science literature therefore establishes the proof of concept that biological adjuncts may improve cartilage repair when used in conjunction with reparative and replacement treatment strategies for osteochondral lesions of the talus. | Niall A Smyth Christopher D Murawski Amgad M Haleem Charles P Hannon Ian Savage-Elliott John G Kennedy | 2012 | World Journal of Orthopedics2012，3，7： | 8 |
| 2 | Vanishing bile duct syndrome in human immunodeficiency virus infected adults:A report of two cases显示文摘Vanishing bile duct syndrome(VBDS) is a group of rare disorders characterized by ductopenia,the progressive destruction and disappearance of intrahepatic bile ducts leading to cholestasis.Described in association with medications,autoimmune disorders,cancer,transplantation,and infections,the specific mechanisms of disease are not known.To date,only 4 cases of VBDS have been reported in human immunodeficiency virus(HIV) infected patients.We report 2 additional cases of HIV-associated VBDS and review the features common to the HIV-associated cases.Presentation includes hyperbilirubinemia,normal liver imaging,and negative viral and autoimmune hepatitis studies.In HIV-infected subjects,VBDS occurred at a range of CD4+ T-cell counts,in some cases following initiation or change in antiretroviral therapy.Lymphoma was associated with two cases;nevirapine,antibiotics,and viral co-infection were suggested as etiologies in the other cases.In HIV-positive patients with progressive cholestasis,early identification of VBDS and referral for transplantation may improve outcomes. | Ana Paula Oppenheimer Christopher Koh Mary McLaughlin John C Williamson Thomas D Norton Jennifer Laudadio Theo Heller David E Kleiner Kevin P High Caryn G Morse | 2013 | World Journal of Gastroenterology2013，19，1： | 8 |
| 3 | Hepatocellular carcinoma after Iocoregional therapy:Magnetic resonance imaging findings in falsely negative exams显示文摘AIM:To elucidate causes for false negative magnetic resonance imaging(MRI)exams by identifying imaging characteristics that predict viable hepatocellular carcinoma(HCC)in lesions previously treated with locoregional therapy when obvious findings of recurrence are absent.METHODS:This retrospective institutional review board-approved and Health Insurance Portability and Accountability Act-compliant study included patients who underwent liver transplantation at our center between 1/1/2000 and 12/31/2012 after being treated for HCC with locoregional therapy.All selected patients had a contrast-enhanced MRI after locoregional therapy within 90 d of transplant that was prospectively interpreted as without evidence of residual or recurrenttumor.Retrospectively,2 radiologists,blinded to clinica and pathological data,independently reviewed the pre transplant MRIs for 7 imaging features.Liver explan histopathology provided the reference standard,with clinically significant tumor defined as viable tumor≥1.0cm in maximum dimension.Fisher’s exact test was firs performed to identify significant imaging features.RESULTS:Inclusion criteria selected for 42 patients with 65 treated lesions.Fourteen of 42 patients(33%and 16 of 65 treated lesions(25%)had clinically significant viable tumor on explant histology.None o the 7 imaging findings examined could reliably and reproducibly determine which treated lesion had viable tumor when the exam had been prospectively read as without evidence of viable HCC.CONCLUSION:After locoregional therapy some treated lesions that do not demonstrate any MRI evidence o HCC will contain viable tumor.As such even patients with a negative MRI following treatment should receive regular short-term imaging surveillance because some have occult viable tumor.The possibility of occult tumo should be a consideration when contemplating any action which might delay liver transplant. | David Becker-Weidman Jesse M Civan Sandeep P Deshmukh Christopher G Roth Steven K Herrine Laurence Parker Donald G Mitchell | 2016 | World Journal of Hepatology2016，8，16： | 2 |
| 4 | Hyperbranched polymer/montmorillonite clay nanocomposites显示文摘 | RODLERT M CHRISTOPHER G P GARAMSZEGI L | 2004 | Polymer2004，45，1： | 1 |
| 5 | Transgenic pigs as bioreactors: a comparison ofgamma-carboxylation of glutamic acid in recombinant humanprotein C and factor Ⅸ by the mammary gland显示文摘 | KEVIN E V C STEPHEN P B CHRISTOPHER G R | 1999 | Genetic Analysis: Biomolecular Engineering1999，15，： | 1 |
| 6 | A Compact Optical Flow Cell for Nurse in Aqueous Halide Determination显示文摘 | Chris D G Peter D Christopher P M | | 0，，04： | 1 |
| 7 | The antiplasmo-dial activity of norcantharidin analogs 显示文摘 | JOANNA B ADAM M C CHRISTOPHER P G | 2010 | Bioorg Med ChemLett2010，20，22： | 1 |
| 8 | Utilization of the less-invasive stabilization system internal fixator for open fractures of the proximal tibia:a multi-center evaluation显示文摘 | James P Stannard Christopher G Finkemeier Jackson Lee | 2008 | Indian J Orthop2008，42，4： | 1 |
| 9 | The Case of Coconuts in Indonesia显示文摘 | Ricardo G Christopher P A | 1991 | Human Ecolog31991，19，1： | 1 |
| 10 | Lipid profiling identifies a triacylglycerol signature of insulin resistance and improves diabetes prediction in humans显示文摘 | Rhee Eugene P Cheng Susan Larson Martin G Walford Geoffrey A Lewis Gregory D McCabe Elizabeth Yang Elaine Farrell Laurie Fox Caroline S O’Donnell Christopher J Carr Steven A Vasan Ramachandran S Florez Jose C Clish Clary B Wang Thomas J Ger | 2011 | Journal of Clinical Investigation2011，，4： | 1 |
| 11 | Chemi cal recycling of carbon fibre composites using alcohols under subcritical and supercritical conditions显示文摘 | RAUL P H JUAN G S CHRISTOPHER D | 2008 | Journal of Super- critical Fluids2008，46，： | 1 |
| 12 | Cystatin C:an improved estimator of glomerular filtration rate显示文摘 | Omar F Laterza Christopher P Mitchell G Scott | 2002 | Clinical Chemistry2002，48，5： | 1 |
| 13 | Spatial learning and memory deficits following exposure to 24 h of sleep fragmentation or intermittent hypoxia in a rat model of obstructive sleep apnea 显示文摘 | Christopher P Warda John G McCoya James T McKena | 2009 | Brain Res2009，1294，： | 1 |
| 14 | Utliziation of the less invasive stabilization system internal fixation for open fractures of the proximal tibia:a multi-center evaluation显示文摘 | James P Stannard Christopher G Finke Meier Jackson Lee | 2008 | Indian J Orthop2008，42，4： | 1 |
| 15 | Feasibility of pancreatectomy following high-dose proton therapy for unresectable pancreatic cancer显示文摘AIM To review surgical outcomes for patients undergoing pancreatectomy after proton therapy with concomitant capecitabine for initially unresectable pancreatic adenocarcinoma.METHODS From April 2010 to September 2013,15 patients with initially unresectable pancreatic cancer were treated withproton therapy with concomitant capecitabine at 1000 mg orally twice daily. All patients received 59.40 Gy(RBE) to the gross disease and 1 patient received 50.40 Gy(RBE) to high-risk nodal targets. There were no treatment interruptions and no chemotherapy dose reductions. Six patients achieved a radiographic response sufficient to justify surgical exploration,of whom 1 was identified as having intraperitoneal dissemination at the time of surgery and the planned pancreatectomy was aborted. Five patients underwent resection. Procedures included:Laparoscopic standard pancreaticoduodenectomy(n = 3),open pyloris-sparing pancreaticoduodenectomy(n = 1),and open distal pancreatectomy with irreversible electroporation(IRE) of a pancreatic head mass(n = 1). RESULTS The median patient age was 60 years(range,51-67). The median duration of surgery was 419 min(range,290-484),with a median estimated blood loss of 850 cm^3(range,300-2000),median ICU stay of 1 d(range,0-2),and median hospital stay of 10 d(range,5-14). Three patients were re-admitted to a hospital within 30 d after discharge for wound infection(n = 1),delayed gastric emptying(n = 1),and ischemic gastritis(n = 1). Two patients underwent R0 resections and demonstrated minimal residual disease in the final pathology specimen. One patient,after negative pancreatic head biopsies,underwent IRE followed by distal pancreatectomy with no tumor seen in the specimen. Two patients underwent R2 resections. Only 1 patient demonstrated ultimate local progression at the primary site. Median survival for the 5 resected patients was 24 mo(range,10-30).CONCLUSION Pancreatic resection for patients with initially unresectable cancers is feasible after high-dose [59.4 Gy(RBE)] proton radiotherapy with a high rate of local control,acceptable surgical morbidity,and a median survival of 24 mo. | Kathryn E Hitchcock R Charles Nichols Christopher G Morris Debashish Bose Steven J Hughes John A Stauffer Scott A Celinski Elizabeth A Johnson Robert A Zaiden Nancy P Mendenhall Michael S Rutenberg | 2017 | World Journal of Gastrointestinal Surgery2017，9，4： | 1 |
| 16 | Cystatln C: An im-proved estimator of glomemlar filtration rate 显示文摘 | Omar F Christopher P Mitchell G | 2002 | Clia them2002，48，： | 1 |
| 17 | The draft genome of the transgenic tropical fruit tree papaya ( Carica pap aya Linnaeus ) 显示文摘 | MING R HOU S B FENG Y YU Q DIONNE-LAPORTE A SAW J H SENIN P WANG W LY B V LEWIS K L T SALZBERG S L FENG L GONES M R SKELTON R L MURRAYJ E CHEN C QIAN W SHEN J DU P EUSTICE M TONG E TANG H LYONS E PAULL R E MICHAEL T P WALL K RICE D W ALBERT H WANG M L ZHU Y J SCHATZ M NAGARAJAN N ACOB R A GUAN P BLAS A WAI C M ACKERMAN C M REN Y LIU C WANG J M WANG J P NA J SHAKIROV E V HAAS B THIMMAPURAM J NELSON D WANG X BOWERS J E GSCHWEND A R DELCHER A L SINGH R SUZUKI J Y TRIPATHI S NEUPANE K WEI H IRIKURA B PAIDI M JIANG N ZHANG W PRESTING G WINDSOR A NAVAJAS-PEREZ R TORRES M J FELTUS A PORTER B LI Y BURROUGHS A M LUO M C LIU L CHRISTOPHER D A MOUNT S M MOORE P H SUGIMURA T JIANG J SCHULER M A FRIEDMAN V MITCHELL-OLDS T SHIPPEN D E PAMPHILIS C W PALMER J D FREELING M PATERSON A H GONSALVES D WANG L ALAM M | 2008 | Nature2008，452，： | 1 |
| 18 | Hyperbranched polymer/montmorillonite clay nanocomposites显示文摘 | Rodlert M Christopher G P Garamszegi L | 2004 | Polymer2004，45，1： | 1 |
| 19 | Use of protein:creatinine ratio measurements on random urine samples for prediction of significant proteinuria: A systematic review显示文摘 | Christopher P P Ronald G N James C B | 2005 | Clinical Chemistry2005，51，9： | 1 |
| 20 | Differential expression of two 1-aminocyclopropane-1-carboxylic acid oxidase genes in Broccoli after harvest显示文摘 | BARRY J P CHRISTOPHER G D KEVIN M D | 1995 | Plant Physiology1995，108，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员